Compass Financial Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$24.9K Buy
+450
New +$24.3K ﹤0.01% 894

Other funds holding CRSP

Compass Financial Management's CRSP Position: Q3 2026 in Review

Compass Financial Management opened a new position in CRISPR Therapeutics (CRSP) in Q3 2026: 450 shares worth $24.9K. The stake represents ﹤0.01% of the portfolio and ranks #894 among its holdings.

504 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Compass Financial Management held 450 shares of CRISPR Therapeutics worth $24.9K as of Q3 2026.
  • CRISPR Therapeutics was a new Compass Financial Management position in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Compass Financial Management's portfolio in Q3 2026, its #894 holding.
  • 504 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Compass Financial Management's 13F filing for Q3 2026, filed 30 Oct 2026.